<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046083</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0177</org_study_id>
    <secondary_id>2013-A00169-36</secondary_id>
    <nct_id>NCT02046083</nct_id>
  </id_info>
  <brief_title>Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers</brief_title>
  <acronym>PITA 3</acronym>
  <official_title>Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The primary purpose of the protocol is to evaluate the efficacy of a protocol for induction&#xD;
      of tolerance to peanut ingestion increasing doses. The secondary purpose is to determine the&#xD;
      interest of a prolonged maintenance therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active&#xD;
      treatment versus placebo for induction phase; 2/ long versus short maintenance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients which tolerate the cumulative dose of 2 grams of peanut at the end of the first phase of 24 weeks between treatment and placebo groups</measure>
    <time_frame>at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients had quadrupled their tolerance to peanut at the end of induction phase</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse effects during induction phase</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifications of the immune profile showing a desensitization to peanut</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients which tolerate the cumulative dose of 2 grams of peanut during a Double-Blind, Placebo-Controlled Food Challenges (DBPCFCs) after 24 weeks without traces eviction diet after the end of maintenance phase</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arachid</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adolescents between 12 and 18 years&#xD;
&#xD;
          -  Clinical History of allergic manifestation within one hour of ingestion of peanuts or&#xD;
             Double-Blind, Placebo-Controlled Food Challenges (DBPCFCs) peanut positive below the&#xD;
             threshold of 2 grams&#xD;
&#xD;
          -  Bad reaction peanut demonstrated by positive Patch Test (PT â‰¥ 3 mm above the negative&#xD;
             control) and specific IgE f13&gt; 12 IU / mL and / or rAra h2&gt; 5.8 IU / mL&#xD;
&#xD;
          -  Previous follow at least 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of response during the initial DBPCFCs to the cumulative dose of 2 grams of&#xD;
             peanut or instant dose of 1 gram of peanut&#xD;
&#xD;
          -  Uncontrolled asthma and / or severe over the previous year&#xD;
&#xD;
          -  Atopic dermatitis uncontrolled&#xD;
&#xD;
          -  Initial severe anaphylaxis requiring hospitalization in intensive care&#xD;
&#xD;
          -  Presence of a major allergy with anaphylaxis at another allergen risk (milk, egg,&#xD;
             nuts, or other)&#xD;
&#xD;
          -  Home away from a center could support a severe reaction in emergency&#xD;
&#xD;
          -  Lack of motivation and understanding of parents and / or child&#xD;
&#xD;
          -  Incapacity&#xD;
&#xD;
               -  to establish a daily logbook of clinical monitoring&#xD;
&#xD;
               -  to support severe reaction after eating peanut&#xD;
&#xD;
               -  to follow a regular peanut ingestion protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc FAUQUERT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>0473751195</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Teenager</keyword>
  <keyword>Peanut</keyword>
  <keyword>OIT (Oral Induction Tolerance)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

